Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 20:13:921385.
doi: 10.3389/fphar.2022.921385. eCollection 2022.

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study

Xiangjun Qi  1 , Yanlong Li  1 , Wei Liu  2 , Yifan Wang  3 , Zhuangzhong Chen  2 , Lizhu Lin  2
Affiliations

Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study

Xiangjun Qi et al. Front Pharmacol. .

Abstract

Background: Antibody-drug conjugate (ADC) is a promising therapy for solid cancer that has raised global concern. Although several papers have reviewed the current state of ADCs in different solid cancers, a quantitative analysis of the publications in this field is scarce. Methods: Publications related to ADC in the field of solid cancer were obtained from the Web of Science Core Collection. Data analyses were performed with VOSviewer 1.6.9, HistCite 2.1, CiteSpace V and R package Bibliometrix. Results: A total of 3,482 records were obtained in the holistic field and 1,197 in the clinical field. Steady growth in the number of publications was observed. The United States was the leading contributor in this field. Krop IE was the most influential author. The most productive institution was Genentech Inc., while Mem Sloan Kettering Canc Ctr was the most cited one. The most impactful journal was the Journal of Clinical Oncology. A total of 37 burst references and five burst references were identified between 2017-2022 in the holistic and clinical fields, respectively. Keywords analysis indicated that ADCs research mainly involved breast cancer, triple-negative breast cancer, ovarian cancer, small cell lung cancer, prostate cancer, gastric cancer, and urothelial carcinoma. ADC agents including trastuzumab emtansine, trastuzumab deruxtecan, sacituzumab govitecan, enfortumab vedotin, and rovalpituzumab tesirine were highly studied. Targets including HER2, trophoblast cell-surface antigen, mesothelin, delta-like ligand 3, and nectin-4 were the major concerns. Conclusion: This study analyzed publications concerning ADCs in the field of solid cancer with bibliometric analysis. Further clinical trials of ADCs and designs of the next generation of ADCs are the current focuses of the field. Acquired resistance of ADCs and biomarkers for ADC therapy efficacy monitoring are future concerns.

Keywords: VOSviewer; antibody-drug conjugate; bibliometric analysis; bibliometrix; citespace; histcite; solid cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Annual publications of ADC research in the field of solid cancer.
FIGURE 2
FIGURE 2
The geographical distribution of the publications and the country collaboration network map. (A) The geographical distribution of publications related to ADC research. (B) Country collaboration in the holistic ADC research field. (C) Country collaboration in the clinical ADC research field.
FIGURE 3
FIGURE 3
The collaboration and overlay map of institutions for ADC research in the solid cancer field. (A,B) The collaboration and overlay map of institutions for holistic ADC research, respectively. (C,D) The collaboration and overlay map of institutions for clinical ADC research, respectively.
FIGURE 4
FIGURE 4
The dual-map overlay of journals and network map of cited journals related to ADC research in the solid cancer field. (A,B). The dual-map overlay of journals for holistic and clinical research, respectively. (C,D). The network map of cited journals for holistic and clinical research, respectively.
FIGURE 5
FIGURE 5
References with continuous citation bursts during the last 5 years.
FIGURE 6
FIGURE 6
The density, co-occurrence, and overlay map of keywords. (The density, co-occurrence, and overlay map are displayed in the first to third columns, respectively.) (A–C). Maps for the holistic ADC research field. (D–F). Maps for the clinical ADC research field.
See this image and copyright information in PMC

References

    1. Abu Saadeh F., Norris L., O'toole S., Mohamed B. M., Langhe R., O'leary J., et al. (2013). Tumour Expresion of Tissue Factor and Tissue Factor Pathway Inhibitor in Ovarian Cancer- Relationship with Venous Thrombosis Risk. Thromb. Res. 132 (5), 627–634. 10.1016/j.thromres.2013.09.016 - DOI - PubMed
    1. Akashi T., Furuya Y., Ohta S., Fuse H. (2003). Tissue Factor Expression and Prognosis in Patients with Metastatic Prostate Cancer. Urology 62 (6), 1078–1082. 10.1016/s0090-4295(03)00768-4 - DOI - PubMed
    1. Argani P., Iacobuzio-Donahue C., Ryu B., Rosty C., Goggins M., Wilentz R. E., et al. (2001). Mesothelin Is Overexpressed in the Vast Majority of Ductal Adenocarcinomas of the Pancreas: Identification of a New Pancreatic Cancer Marker by Serial Analysis of Gene Expression (SAGE). Clin. Cancer Res. 7 (12), 3862–3868. - PubMed
    1. Aria M., Cuccurullo C. (2017). Bibliometrix: An R-tool for Comprehensive Science Mapping Analysis. Journal of Informetrics 11 (4), 959–975. 10.1016/j.joi.2017.08.007 - DOI
    1. Banerji U., Van Herpen C. M. L., Saura C., Thistlethwaite F., Lord S., Moreno V., et al. (2019). Trastuzumab Duocarmazine in Locally Advanced and Metastatic Solid Tumours and HER2-Expressing Breast Cancer: a Phase 1 Dose-Escalation and Dose-Expansion Study. Lancet Oncol. 20 (8), 1124–1135. 10.1016/S1470-2045(19)30328-6 - DOI - PubMed